Table 3.
Other outcomes
| Arm | ‘group’ | ‘individual’ | ‘standard’ |
|---|---|---|---|
| Mean (SD), n | |||
| EQ-5D pre | 0.545 (0.255), 19 | 0.480 (0.250), 20 | 0.555 (0.274), 19 |
| EQ-5D 14w | 0.639 (0.308), 17 | 0.660 (0.227), 14 | 0.560 (0.271), 13 |
| OKS pre | 22.8 (7.4), 20 | 22.4 (6.8), 20 | 24.2 (5.8), 20 |
| OKS 14w | 32.3 (11.1), 17 | 29.6 (7.7), 15 | 27.2 (7.7), 13 |
| Using NSAID daily, n/N | |||
| pre | 11/20 (55 %) | 8/20 (40 %) | 10/20 (50 %) |
| 14w | 5/17 (29 %) | 4/14 (29 %) | 7/14 (50 %) |
| Troublesomea, n/N | |||
| pre | 7/20 (35 %) | 9/20 (45 %) | 5/20 (25 %) |
| 14w | 3/17 (18 %) | 2/15 (13 %) | 3/14 (21 %) |
| Global changeb n/N | |||
| 14w | 7/17 (41 %) | 9/15 (60 %) | 2/14 (14 %) |
Pre baseline, 14w 14 week follow-up, ‘group’ group acupuncture, ‘individual’ individual acupuncture, ‘standard’ standardised care only, NSAID non-steroidal anti-inflammatory drug
aHighest two categories, extremely and very
bHighest two categories, much or moderately better